Eli Lilly (LLY) stock under spotlight with $3B China investment, orforglipron approval filing, and LillyConnect platform launch. Analysts maintain bullish outlook.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly (NYSE:LLY) and Samsung Biologics have agreed to launch a Gateway Labs partnership in Korea. The collaboration will create a new facility offering lab space, operational support, and access ...

Our position in American pharmaceutical company, Eli Lilly & Company (1.8%), was a top contributor to relative returns during the fourth quarter.

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Wednesday's key moments. 1. The S & P 500 drifted lower Wednesday as Wall ...

Dupixent growth offsets Eylea declines; pipeline/Libtayo impact post-2026; monitor ROIC & SBC. Click for a REGN update.

Eli Lilly and Company (NYSE:LLY) said it intends to invest about $3 billion in China over the next ten years to expand manufacturing capacity for its experimental treatment for type 2 diabetes and ...

Eli Lilly & Co will invest $3 billion in China over the next decade to expand local production, with a focus on weight loss as the US drugmaker looks to cement its dominance in the booming obesity ...

Wolfe said the oral GLP-1 therapy could broaden the obesity treatment market because it combines strong weight-loss results ...

The Investment Committee give you their top stocks to watch for the second half.

We continue to favour the stock for long term investment.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of ...